So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors [0.03%]
如此多的选择，如此微薄的价值：通过选择具有成本效益的质子泵抑制剂来节约潜在费用
Hye-Young Kwon
Hye-Young Kwon
Background: Given that Korea lacks measures to promote cost-effective prescribing, this study investigated the efficiency of prescribers' decision-making when faced with the choice of 398 products containing 15 proton pum...
Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal [0.03%]
葡萄牙三阴性乳腺癌的疾病负担和疾病成本
Joana Silva,Gabriela Sousa,Luís Costa et al.
Joana Silva et al.
Background: Triple-negative breast cancer accounts for 15% of all breast cancer cases, and it has a lower survival rate and higher incidence of early recurrence, particularly during the first 10 years after diagnosis. ...
COVID-19 Vaccine Preferences in China: A Comparison of Discrete Choice Experiment and Profile Case Best-Worst Scaling [0.03%]
中国新冠疫苗偏好：分组选择实验和配置案例最佳-最差量表的对比研究
Enxue Chang,Yanni Jia,Xiaoying Zhu et al.
Enxue Chang et al.
Objectives: Little is known about the diversity of residents' preferences for COVID-19 vaccines during the time when COVID-19 management was downgraded in China. This study aims to investigate these preferences using disc...
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer [0.03%]
用于治疗晚期非小细胞肺癌的潜在预测生物标志物的非常早期的卫生技术评估
Leila-Sophie Otten,Alessandra I G Buma,Berber Piet et al.
Leila-Sophie Otten et al.
Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. How...
Correction: From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment [0.03%]
关于“从临床到非临床结局的HIV治疗：经济及组织影响评估”的勘误说明
Lucrezia Ferrario,Barbara Menzaghi,Giuliano Rizzardini et al.
Lucrezia Ferrario et al.
Published Erratum
PharmacoEconomics - open. 2025 Jan 24. DOI:10.1007/s41669-025-00558-2 2025
Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England [0.03%]
英国心肌梗死后患者植入式心脏除颤器的成本效益分析
Vasileios Kontogiannis,Farai Goromonzi,Brigitte Both et al.
Vasileios Kontogiannis et al.
Background: Patients with a left ventricular ejection fraction ≤ 35% are at increased risk of sudden cardiac death (SCD) within the first months after a myocardial infarction (MI). The wearable cardioverter defibrillator...
Maria Grazia Ursino,Annalisa Milano,Filippo Viti De Angelis et al.
Maria Grazia Ursino et al.
Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount...
Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis [0.03%]
司美格鲁肽2.4毫克与利拉鲁肽3毫克在希腊肥胖症治疗中的短期成本效益分析
Panagiotis Papantoniou,Nikolaos Maniadakis
Panagiotis Papantoniou
Background: Obesity is a global health issue with significant economic implications for health systems. Pharmacotherapy, including semaglutide 2.4 mg and liraglutide 3 mg, offers a treatment option for weight management; ...
Correction: Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data [0.03%]
更正：使用瑞典人口数据将世界卫生组织残疾评估表（WHODAS 2.0）映射到SF-6D上
Anna Philipson,Lars Hagberg,Liselotte Hermansson et al.
Anna Philipson et al.
Published Erratum
PharmacoEconomics - open. 2025 Jan 9. DOI:10.1007/s41669-024-00549-9 2025
Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany [0.03%]
德国镰状细胞病反复血管阻塞危机和输血依赖性β-地中海贫血常规管理相关的临床并发症和医疗资源利用情况
Chuka Udeze,Nanxin Li,Colin Kunzweiler et al.
Chuka Udeze et al.
Objective: The purpose of this study was to describe clinical complications and healthcare resource utilization (HCRU) among patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) and patients...